Related Experiment Video

Updated: Oct 4, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined

    Journal of Hepatocellular Carcinoma
    |February 4, 2022
    PubMed

    Abstract:

    [This retracts the article DOI: 10.2147/JHC.S338309.].

    More Related Videos

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    5.7K
    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    648

    Related Experiment Videos

    Last Updated: Oct 4, 2025

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    10.4K
    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    5.7K
    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    648

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    5.1K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.9K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Prognosis and Safety of Neoadjuvant Therapy Plus Surgery versus Upfront Surgery in Patients with Resectable Hepatocellular Carcinoma at CNLC Ib-IIa Stage: A Propensity Score Matching Study.

    Journal of hepatocellular carcinoma·2026

    MRI-Based Radiomics Predicts FAP Expression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma.

    Journal of hepatocellular carcinoma·2026

    Viral Hepatitis, Potential Aflatoxin B1 Exposure, and Projected Metabolic Risk Factors for Hepatocellular Carcinoma in Somalia: A Call for Integrated Prevention, Surveillance, and Research.

    Journal of hepatocellular carcinoma·2026

    Prognostic Implications of Nitrogen Metabolism-Related Gene SMS in Hepatocellular Carcinoma: An Integrated Bioinformatics and Experimental Research.

    Journal of hepatocellular carcinoma·2026

    A Hypoxia and EMT-Related Gene Signature for Predicting Prognosis and Immunotherapy Benefit in Hepatocellular Carcinoma.

    Journal of hepatocellular carcinoma·2026

    The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study.

    Journal of hepatocellular carcinoma·2026

    Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke.

    The New England journal of medicine·2026

    Life-Saving Emergency Decompression via a Clamshell Approach for Cardiac Arrest Caused by Hemorrhage of a Giant Mediastinal Ectopic Thyroid: A Case Report.

    Surgical case reports·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us